Compare FEIM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | KROS |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 584.9M |
| IPO Year | N/A | 2020 |
| Metric | FEIM | KROS |
|---|---|---|
| Price | $46.95 | $16.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $42.50 | $23.00 |
| AVG Volume (30 Days) | 178.3K | ★ 266.1K |
| Earning Date | 03-12-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.76 | N/A |
| EPS | ★ 2.17 | 1.57 |
| Revenue | $69,852,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $5.52 | $6,924.79 |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $21.57 | ★ $10.53 |
| Revenue Growth | 16.06 | ★ 37798.31 |
| 52 Week Low | $13.69 | $9.12 |
| 52 Week High | $61.47 | $22.55 |
| Indicator | FEIM | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 33.11 |
| Support Level | $43.76 | $16.31 |
| Resistance Level | $53.97 | $17.17 |
| Average True Range (ATR) | 4.25 | 0.64 |
| MACD | -1.26 | -0.14 |
| Stochastic Oscillator | 19.58 | 9.57 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.